In the latest trading session, 0.53 million Rocket Pharmaceuticals Inc (NASDAQ:RCKT) shares changed hands as the company’s beta touched 1.13. With the company’s most recent per share price at $5.24 changing hands around $0.05 or 1.06% at last look, the market valuation stands at $559.27M. RCKT’s current price is a discount, trading about -414.89% off its 52-week high of $26.98. The share price had its 52-week low at $4.60, which suggests the last value was 12.21% up since then. When we look at Rocket Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 3.96 million shares, with the 3-month average coming to 1.89 million.
Analysts gave the Rocket Pharmaceuticals Inc (RCKT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.12. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended RCKT as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Rocket Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.58.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Instantly RCKT is in green as seen in intraday trades today. With action -9.72%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -58.27%, with the 5-day performance at -9.72% in the red. However, in the 30-day time frame, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) is -38.94% down. Looking at the short shares, we see there were 11.05 million shares sold at short interest cover period of 8.06 days.
The consensus price target for the stock as assigned by Wall Street analysts is 35.5, meaning bulls need an upside of 85.24% from its recent market value. According to analyst projections, RCKT’s forecast low is 32 with 39 as the target high. To hit the forecast high, the stock’s price needs a -644.27% plunge from its current level, while the stock would need to soar -510.69% for it to hit the projected low.
Rocket Pharmaceuticals Inc (RCKT) estimates and forecasts
Consensus estimates given by 10 financial analysts project the company’s revenue in the current quarter to hit an average of 800k. 10 analysts are of the opinion that Rocket Pharmaceuticals Inc’s revenue for the current quarter will be 1M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.60%. The 2025 estimates are for Rocket Pharmaceuticals Inc earnings to increase by 10.43%, but the outlook for the next 5-year period is at 73.89% per year.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.02% of Rocket Pharmaceuticals Inc shares while 106.98% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 110.30%. There are 106.98% institutions holding the Rocket Pharmaceuticals Inc stock share, with RTW INVESTMENTS, LP the top institutional holder. As of 2024-06-30, the company held 18.8677% of the shares, roughly 17.69 million RCKT shares worth $380.82 million.
WELLINGTON MANAGEMENT GROUP LLP holds the second largest percentage of outstanding shares, with 9.7665% or 9.16 million shares worth $197.12 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund. With 7.6 shares estimated at $39.43 million under it, the former controlled 7.13% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held about 2.46% of the shares, roughly 2.62 shares worth around $13.61 million.
